A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

The purpose of this study is to assess the safety and tolerability of REGN421 (SAR153192) in patients with advanced solid malignancies.

Phase 1

Regeneron Pharmaceuticals

Sanofi